- Home
- COHR vs EXEL Comparison
COHR vs EXEL Comparison
Compare COHR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHR
- EXEL
- Stock Information
- Founded
- COHR 1971
- EXEL 1994
- Country
- COHR United States
- EXEL United States
- Employees
- COHR N/A
- EXEL N/A
- Industry
- COHR Electronic Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COHR Technology
- EXEL Health Care
- Exchange
- COHR Nasdaq
- EXEL Nasdaq
- Market Cap
- COHR 9.8B
- EXEL 9.8B
- IPO Year
- COHR 1987
- EXEL 2000
- Fundamental
- Price
- COHR $75.40
- EXEL $43.64
- Analyst Decision
- COHR Strong Buy
- EXEL Buy
- Analyst Count
- COHR 16
- EXEL 18
- Target Price
- COHR $102.50
- EXEL $38.76
- AVG Volume (30 Days)
- COHR 3.6M
- EXEL 3.9M
- Earning Date
- COHR 05-07-2025
- EXEL 05-13-2025
- Dividend Yield
- COHR N/A
- EXEL N/A
- EPS Growth
- COHR N/A
- EXEL 237.58
- EPS
- COHR N/A
- EXEL 2.20
- Revenue
- COHR $5,595,041,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- COHR $25.33
- EXEL $10.39
- Revenue Next Year
- COHR $9.02
- EXEL $10.74
- P/E Ratio
- COHR N/A
- EXEL $19.53
- Revenue Growth
- COHR 21.67
- EXEL 24.49
- 52 Week Low
- COHR $45.58
- EXEL $20.40
- 52 Week High
- COHR $113.60
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- COHR 53.12
- EXEL 59.93
- Support Level
- COHR $77.75
- EXEL $42.21
- Resistance Level
- COHR $83.55
- EXEL $43.75
- Average True Range (ATR)
- COHR 3.27
- EXEL 1.60
- MACD
- COHR -0.44
- EXEL -0.09
- Stochastic Oscillator
- COHR 19.62
- EXEL 53.96
About COHR Coherent Corp.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.